Corbeau Iléana, Jacot William, Guiu Séverine
Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), 208 Avenue des Apothicaires, 34 298 Montpellier, France.
IRCM, INSERM U1194, Univerité de Montpellier, ICM, 208 Avenue des Apothicaires, 34 298 Montpellier, France.
Cancers (Basel). 2020 Apr 13;12(4):958. doi: 10.3390/cancers12040958.
Inflammatory blood markers (IBM), such as the neutrophil to lymphocyte ratio (NLR), have emerged as potential prognostic factors in various cancers, including breast cancer (BC), potentially allowing an easy, minimally invasive evaluation of a given cancer's prognosis and treatment outcome. We report here a systematic overview of the published data evaluating NLR as a prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC. A total of 45 articles were identified. NLR was found to be an independent prognostic factor for survival in most of the adjuvant treatment studies. However, no significant correlation was found between survival and NLR for early BC patients receiving neo-adjuvant chemotherapy (NACT) and advanced BC patients. Most studies failed to find a significant correlation between NLR and PCR after NACT. Finally, some data showed that IBM could be predictive of chemotherapy-related toxicity.
炎症血液标志物（IBM），如中性粒细胞与淋巴细胞比值（NLR），已成为包括乳腺癌（BC）在内的各种癌症的潜在预后因素，有可能实现对特定癌症预后和治疗结果的简便、微创评估。我们在此报告已发表数据的系统综述，这些数据评估了NLR作为早期和晚期BC病理完全缓解（PCR）及毒性的预后因素或预测因素。共识别出45篇文章。在大多数辅助治疗研究中，NLR被发现是生存的独立预后因素。然而，接受新辅助化疗（NACT）的早期BC患者和晚期BC患者的生存与NLR之间未发现显著相关性。大多数研究未能发现NACT后NLR与PCR之间存在显著相关性。最后，一些数据表明IBM可预测化疗相关毒性。
Zotero 插件